BIOMEA FUSION INC. - COMMON STOCK

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

17 ديسمبر 2024 08:10:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

16 ديسمبر 2024 18:15:01 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

12 ديسمبر 2024 17:02:21 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

09 ديسمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

06 ديسمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

02 ديسمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

18 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

01 نوفمبر 2024 16:05:51 بحسب Nasdaq GlobeNewswire

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

30 أكتوبر 2024 16:00:48 بحسب Nasdaq GlobeNewswire

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

29 أكتوبر 2024 16:46:08 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

21 أكتوبر 2024 09:00:29 بحسب Nasdaq GlobeNewswire

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

15 أكتوبر 2024 16:05:19 بحسب Nasdaq GlobeNewswire

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

07 أكتوبر 2024 09:00:41 بحسب Nasdaq GlobeNewswire

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

01 أكتوبر 2024 09:00:01 بحسب Nasdaq GlobeNewswire

FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

26 سبتمبر 2024 14:00:57 بحسب Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

01 أغسطس 2024 16:05:20 بحسب Nasdaq GlobeNewswire

Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights

31 يوليو 2024 16:05:22 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

06 يونيو 2024 16:05:53 بحسب Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

03 يونيو 2024 16:05:29 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

30 مايو 2024 09:12:39 بحسب Nasdaq GlobeNewswire